RC
STRO icon

RBF Capital’s Sutro Biopharma STRO Stock Holding History

RBF Capital’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$507K Hold
15,272
– – 0.02% 385
2026
Q1 		$380K Hold
15,272
– – 0.02% 399
2025
Q4 		$177K Buy
15,272
+1
+0% +$9 0.01% 526
2025
Q3 		$133K Sell
15,271
-729
-5% -$6.2K 0.01% 546
2025
Q2 		$114K Buy
+16,000
New +$131K 0.01% 566

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

RBF Capital's STRO Position: Q2 2026 in Review

RBF Capital held its Sutro Biopharma (STRO) position steady in Q2 2026 at 15,272 shares worth $507K. The position accounts for 0.02% of the portfolio, ranked #385.

RBF Capital first reported a position in STRO in Q2 2025 and has held it in 5 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • RBF Capital held 15,272 shares of Sutro Biopharma worth $507K as of Q2 2026.
  • RBF Capital left its Sutro Biopharma share count unchanged in Q2 2026.
  • Sutro Biopharma made up 0.02% of RBF Capital's portfolio in Q2 2026, its #385 holding.
  • RBF Capital first reported a position in Sutro Biopharma in Q2 2025 and has held it in 5 quarters since.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on RBF Capital's 13F filing for Q2 2026, filed 14 Aug 2026.